Update | Ordinary Index Rebalancing in the Solactive Pharma Breakthrough Value Index | September 2020

Please find the update to the announcement published on September 10, 2020. MESOBLAST LTD ORD and NOVARTIS AG will stay in the index and NOVARTIS AG-ADR will not be included in the index.

In the ordinary rebalance the following composition will be implemented effective open 21.09.2020:

ALEXION PHARMACEUTICALS INC
BASILEA PHARMACEUTICA LTD.
BEIGENE LTD-ADR
BIOGEN INC
BIOMARIN PHARMACEUTICAL INC
BRISTOL-MYERS SQUIBB CO
CHUGAI PHARMACEUTICAL CO LTD ORD
CSL LTD ORD
EISAI
GENMAB A/S
HALOZYME THERAPEUTICS INC
HORIZON THERAPEUTICS PLC
INCYTE CORP
IONIS PHARMACEUTICALS INC
IPSEN SA
JAZZ PHARMACEUTICALS PLC
KYOWA KIRIN CO LTD
MESOBLAST LTD ORD
NEKTAR THERAPEUTICS
NIPPON SHINYAKU CO LTD
NOVARTIS AG
OXFORD BIOMEDICA PLC
ROCHE HOLDING AG
SAREPTA THERAPEUTICS INC
SEATTLE GENETICS INC
SWEDISH ORPHAN BIOVITRUM AB
TORII PHARMACEUTICAL CO LTD
ULTRAGENYX PHARMACEUTICAL INC
UNITED THERAPEUTICS CORP
VERTEX PHARMACEUTICALS INC